Skip to main content
SpringerLink
Log in

Lyophilized Formulations of Recombinant Tumor Necrosis Factor

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Recombinant tumor necrosis factor-alpha (TNF), an investigational biological response modifier, is a protein and is susceptible to particulate generation during handling in dilute aqueous solutions. TNF is prone to formation of nonreducible dimers and oligomers during formulation, lyophilization, and storage. The effect of various parameters, such as the pH, protein concentration, and nature of excipients present during lyophilization, on the formation of nonreducible dimers and oligomers was investigated. The results of these studies indicate that these parameters can significantly alter the rate of this reaction. Inclusion of an amorphous buffer and an appropriate amount of a crystallizing sugar (mannitol) combined with a suitable quantity of an amorphous protectant (dextran, sucrose, trehalose, or 2-hydroxypropyl-β-cyclodextrin) was shown to reduce the formation of these dimeric and oligomeric species during lyophilization. Representative lyophilized formulations of TNF based on selected amorphous excipients were found to be fully bioactive and stable over 9 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. L. Fransen, M. R. Ruysschaert, J. Van der Heyden, and W. Fiers. Recombinant tumor necrosis factor. Species specificity for a variety of human and murine transformed cell lines. Cell. Immunol. 100:260–267 (1986).

    Google Scholar 

  2. R. Phillip and L. B. Epstein. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxity induced by itself, γ-interferon, and interleukin-1. Nature 323:86–89 (1986).

    Google Scholar 

  3. B. B. Aggarwal, W. J. Kohr, P. E. Hass, B. Moffat, S. A. Spencer, W. J. Henzel, T. S. Bringman, G. E. Nedwin, D. V. Goeddel, and R. N. Harkins. Human tumor necrosis factor: Production, purification, and characterization. J. Biol. Chem. 260:2345–2354 (1985).

    Google Scholar 

  4. A. M. Wang, A. A. Creasey, M. B. Ladner, L. S. Lin, J. Stickler, J. N. Van Arsdell, R. Yamamoto, and D. F. Mark. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149–154 (1985).

    Google Scholar 

  5. C. Grunfeld and M. A. Palladino, Jr. Tumor necrosis factor: Immunologic, antitumor, metabolic, and cardiovascular activities. Adv. Intern. Med. 35:45–71 (1990).

    Google Scholar 

  6. P. Wingfield, R. H. Pain, and S. Craig. Tumor necrosis factor is a compact trimer. FEBS Lett. 211:179–184 (1987).

    Google Scholar 

  7. R. A. Smith and C. Bagiloni. The active form of tumor necrosis factor is a trimer. J. Biol. Chem. 262:6951–6954 (1987).

    Google Scholar 

  8. K. S. Lam, P. Scuderi, and S. E. Salmon. Analysis of the molecular organization of recombinant human tumor necrosis factor (rTNF) in solution using ethylene glycolbis (succinimidyl-succinate) as the cross-linking reagent. J. Biol. Resp. Mod. 7:267–275 (1988).

    Google Scholar 

  9. A. A. Creasey, L. V. Doyle, M. T. Reynolds, T. Jung, L. S. Lin, and C. R. Vitt. Biological effects of recombinant tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res. 47:145–149 (1987).

    Google Scholar 

  10. D. F. Mark, A. M. Wang, M. B. Ladner, A. A. Creasey, L. S. Lin, and J. Van Arsdell. Human tumor necrosis factor. U.S. Patent No. 4,677,063 (1987).

  11. H. Tada, O. Shiko, K.-I. Kuroshima, and K. Tsukamoto. An improved colorimetric assay for interleukin-2. J. Immunol. Methods 93:157–165 (1986).

    Google Scholar 

  12. U. R. Laemmli. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 (1970).

    PubMed  Google Scholar 

  13. A. P. MacKenzie. Freeze-drying of aqueous solutions containing peptides and proteins. In D. Marshak and D. Liu (eds.), Therapeutic Peptides and Proteins: Formulation, Delivery, and Targeting, Cold Spring Harbor, New York, 1989, pp. 17–21.

    Google Scholar 

  14. H. Levine and L. Slade. Principles of “cryostabilization” technology from structure/property relationships of carbohydrate/water systems—A review. Cryo-Letters 9:21–63 (1988).

    Google Scholar 

  15. L. van den Berg and D. Rose. Effect of freezing on the pH and composition of sodium and potassium phosphate solutions: The reciprocal system KH2PO4 ⋅ Na2HPO4 ⋅ H2O. Arch. Biochem. Biophys. 81:319–329 (1959).

    Google Scholar 

  16. F. Franks. Biophysics and Biochemistry at Low Temperatures, Cambridge University Press, Cambridge, 1985, p. 59.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cetus Corporation, 1400 Fifty-Third Street, Emeryville, California, 94608

    Maninder S. Hora, Rajsharan K. Rana & Flint W. Smith

Authors
  1. Maninder S. Hora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajsharan K. Rana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Flint W. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hora, M.S., Rana, R.K. & Smith, F.W. Lyophilized Formulations of Recombinant Tumor Necrosis Factor. Pharm Res 9, 33–36 (1992). https://doi.org/10.1023/A:1018919508463

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018919508463

Search

Navigation